#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

### FORM 10-Q

### 

for the Quarterly Period ended September 30, 2023;

□ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from \_\_\_\_\_ to \_\_\_\_

ZION OIL & GAS, INC. – File Number 001-33228 (Exact name of registrant as specified in its charter)

Delaware	20-0065053		
(State or other jurisdiction of	(I.R.S. Employer		
incorporation or organization)	Identification No.)		
12655 N Central Expressway, Suite 1000, Dallas, TX	75243		

(Address of principal executive offices)

Zip Code

(214) 221-4610

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  $\boxtimes$  No  $\square$ 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  $\boxtimes$  No  $\square$ 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer □ Non-accelerated filer □ Accelerated filer□Smaller reporting company⊠Emerging growth company□

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  $\Box$  No  $\boxtimes$ 

As of November 7, 2023, Zion Oil & Gas, Inc. had outstanding 605,319,057 shares of common stock, par value \$0.01 per share.

# INDEX PAGE

	Page
PART I — FINANCIAL INFORMATION	
Item 1 – Financial Statements – Unaudited	
Consolidated Condensed Balance Sheets – September 30, 2023 and December 31, 2022	1
Consolidated Condensed Statements of Operations for the three and nine months ended September 30, 2023 and 2022	2
Consolidated Condensed Statement of Changes in Stockholders' Equity for the three and nine months ended September 30, 2023 and 2022	3
Consolidated Condensed Statements of Cash Flows for the nine months ended September 30, 2023 and 2022	5
Notes to Consolidated Condensed Financial Statements	7
Item 2 – Management's Discussion and Analysis of Financial Condition and Results of Operations	35
Item 3 – Quantitative and Qualitative Disclosures About Market Risk	43
Item 4 – Controls and Procedures	43
PART II — OTHER INFORMATION	
Item 1 – Legal Proceedings	44
Item 1A – Risk Factors	44
Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	44
Item 3 – Defaults upon Senior Securities	44
Item 4 – Mine Safety Disclosures	44
Item 5 – Other Information	44
<u>Item 6 – Exhibits</u>	45
Exhibit Index	45
SIGNATURES	46

i

## Consolidated Condensed Balance Sheets as of

	2023	December 31, 2022
	US\$	US\$
	thousands	thousands
	(Unaudited)	
Current assets		
Cash and cash equivalents	510	,
Fixed short term bank and escrow deposits – restricted	1,020	
Prepaid expenses and other current assets	233	600
Other deposits	-	483
Governmental receivables	10	
Other receivables	156	
Total current assets	1,929	4,607
Unproved oil and gas properties, full cost method (see Note 4)	16,342	15,889
Property and equipment at cost		
Drilling rig and related equipment, net of accumulated depreciation of \$2,025 and		
\$1,455 (see note 2I)	5,700	6,281
Property and equipment, net of accumulated depreciation of \$678 and \$647	81	112
	5,781	6,393
Right of Use Lease Assets (see Note 5)	246	202
Other assets		
Assets held for severance benefits	436	424
Total other assets	436	424
Total assets	24,734	27,515
Liabilities and Stockholders' Equity		
Current liabilities		
Accounts payable	862	2,147
Lease obligation – current (see Note 5)	192	196
Asset retirement obligation	571	571
Accrued liabilities	412	1,032
Total current liabilities	2,037	3,946
Long-term liabilities		
Lease obligation – non-current (see Note 5)	53	
Provision for severance pay	467	457
Total long-term liabilities	520	469
Total liabilities	2,557	4,415

Commitments and contingencies (see Note 6)

Stockholders' equity		
Common stock, par value \$.01; Authorized: 1,200,000,000 shares at		
September 30, 2023: Issued and outstanding: 602,554,266 and 524,231,493		
shares at September 30, 2023 and December 31, 2022, respectively	6,026	5,242
Additional paid-in capital	300,969	296,460
Accumulated deficit	(284,818)	(278,602)
Total stockholders' equity	22,177	23,100
Total liabilities and stockholders' equity	24,734	27,515

The accompanying notes are an integral part of the unaudited interim consolidated condensed financial statements.

## Consolidated Condensed Statements of Operations (Unaudited)

		r the three months ended For the nine mont September 30, September 3			
	2023	2022	2023	2022	
	US\$	US\$	US\$	US\$	
	thousands	thousands	thousands	thousands	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
General and administrative	1,332	1,636	4,106	4,621	
Post impairment of unproved oil and gas properties	36	-	129	-	
Other	379	719	1,978	2,376	
Loss from operations	(1,747)	(2,355)	(6,213)	(6,997)	
Other income (expense), net					
Foreign exchange gain (loss)	2	(2)		(92)	
Financial income (expenses), net	2	(17)	(1)	(48)	
Loss, before income taxes	(1,743)	(2,374)	) (6,216)	(7,137)	
Income taxes	(1,743)	(2,374)	(0,210)	(7,137)	
income taxes					
Net loss	(1,743)	(2,374)	(6,216)	(7,137)	
Net loss per share of common stock					
<b>Basic and diluted (in US\$)</b>	(0.003)	(0.01)	(0.011)	(0.02)	
Weighted-average shares outstanding					
Basic and diluted (in thousands)	578,497	484,678	551,551	454,890	

The accompanying notes are an integral part of the unaudited interim consolidated condensed financial statements.

# Consolidated Condensed Statement of Changes in Stockholders' Equity (Unaudited)

## For the three and nine months ended September 30, 2023

	Commo	on Stock	Additional paid-in	Accumulated	
	Shares	Amounts	Capital	deficit	Total
	thousands	US\$ <u>thousands</u>	US\$ <u>thousands</u>	US\$ thousands	US\$ thousands
Balances as of December 31, 2022	524,231	5,242	296,460	(278,602)	23,100
Funds received from sale of DSPP units and					
shares and exercise of warrants	78,173	782	4,186	_	4,968
Funds received from option exercises	150	2	10	_	12
Costs associated with the issuance of shares			(610)	_	(610)
Value of options granted to employees, directors and others as non-cash					
compensation			923	_	923
Net loss				(6,216)	(6,216)
Balances as of September 30, 2023	602,554	6,026	300,969	(284,818)	22,177

\* Less than one thousand.

	Commo	on Stock	Additional paid-in	Accumulated	
	Shares	Amounts	Capital	deficit	Total
	thousands	US\$ <u>thousands</u>	US\$ thousands	US\$ thousands	US\$ thousands
Balances as of June 30, 2023	560,449	5,604	299,321	(283,075)	21,850
Funds received from sale of DSPP units and					
shares and exercise of warrants	42,105	422	1,820	_	2,242
Funds received from option exercises	<u> </u>	—		—	
Costs associated with the issuance of shares			(437)	—	(437)
Value of options granted to employees, directors and others as non-cash					
compensation			265	—	265
Net loss	—			(1,743)	(1,743)
Balances as of September 30, 2023	602,554	6,026	300,969	(284,818)	22,177

		on Stock	Additional paid-in	Accumulated	
	Shares	Amounts	Capital	deficit	Total
	thousands	US\$ thousands	US\$ thousands	US\$ thousands	US\$ thousands
D 1 (D 1 21 2021					
Balances as of December 31, 2021 Funds received from sale of DSPP units and	364,324	3,643	277,258	(223,525)	57,376
shares and exercise of warrants	122 451	1 225	15 145		16 470
	132,451 325	1,325	15,145		16,470 3
Funds received from option exercises	525	3		_	5
Value of options granted to employees, directors and others as non-cash					
compensation			1,154		1,154
Net loss	_	_	1,154	(7,137)	(7,137)
	407.100	4.071	202.557		
Balances as of September 30, 2022	497,100	4,971	293,557	(230,662)	67,866
			Additional		
		on Stock	Additional paid-in	Accumulated	
	Commo Shares	on Stock Amounts		Accumulated deficit	Total
			paid-in		<u>Total</u> US\$
		Amounts	paid-in Capital	deficit	
Balances as of June 30, 2022	Shares	Amounts US\$	paid-in Capital US\$	deficit US\$	US\$
Balances as of June 30, 2022 Funds received from sale of DSPP units and	Shares thousands	Amounts US\$ thousands	paid-in Capital US\$ thousands	deficit US\$ thousands	US\$ thousands
	Shares thousands	Amounts US\$ thousands	paid-in Capital US\$ thousands	deficit US\$ thousands	US\$ thousands
Funds received from sale of DSPP units and shares and exercise of warrants	Shares thousands 473,778	Amounts US\$ thousands 4,738	paid-in Capital US\$ thousands 289,792	deficit US\$ thousands	US\$ thousands 66,242
Funds received from sale of DSPP units and	Shares thousands 473,778 23,102	Amounts US\$ thousands 4,738 231	paid-in Capital US\$ thousands 289,792	deficit US\$ thousands	US\$ thousands 66,242 3,477
Funds received from sale of DSPP units and shares and exercise of warrants Funds received from option exercises Value of options granted to employees,	Shares thousands 473,778 23,102	Amounts US\$ thousands 4,738 231	paid-in Capital US\$ thousands 289,792	deficit US\$ thousands	US\$ thousands 66,242 3,477
Funds received from sale of DSPP units and shares and exercise of warrants Funds received from option exercises Value of options granted to employees, directors and others as non-cash	Shares thousands 473,778 23,102	Amounts US\$ thousands 4,738 231	paid-in Capital US\$ thousands 289,792 3,246	deficit US\$ thousands	US\$ thousands 66,242 3,477 2

## For the three and nine months ended September 30, 2022

\* Less than one thousand.

The accompanying notes are an integral part of the unaudited interim consolidated condensed financial statements.

## Consolidated Condensed Statements of Cash Flows (Unaudited)

	For nine mon Septem	ths ended
	2023	2022
	US\$	US\$
	thousands	thousands
	(Unaudited)	
Cash flows from operating activities	(Unauunteu)	(Unauunteu)
Net loss	(6,216)	(7,137)
Adjustments required to reconcile net loss to net cash used in operating activities:	(0,210)	(7,157)
Depreciation	601	593
Cost of options issued to employees, directors and others as non-cash compensation	923	1,137
Post impairment of unproved oil and gas properties	129	1,157
Change in assets and liabilities, net:	14/	
Other deposits	483	73
Prepaid expenses and other	367	196
Governmental receivables	257	631
Lease obligation – current	(256)	
Lease obligation – current	41	(112)
Right of use lease assets	208	194
Other receivables	(13)	
Severance payable, net	(15)	
Accounts payable	(300)	(350)
Accrued liabilities	(131)	59
		(4,719)
Net cash used in operating activities	(3,909)	(4,/19)
Cash flows from investing activities		
Acquisition of property and equipment	-	(17)
Acquisition of drilling rig and related equipment	-	(373)
Investment in unproved oil and gas properties	(2,045)	(12,943)
Net cash used in investing activities	(2,045)	(13,333)
0		
Cash flows from financing activities		
Proceeds from exercise of stock options	12	3
Costs paid related to the issuance of new shares	(610)	-
Proceeds from issuance of stock and exercise of warrants	4,968	16,470
Net cash provided by financing activities	4,370	16,473
Net (decrease)/increase in cash, cash equivalents and restricted cash	(1,584)	
Cash, cash equivalents and restricted cash – beginning of period	3,114	5,952
Cash, cash equivalents and restricted cash – end of period	1,530	4,373
Supplemental schedule of cash flow information		
Non-cash investing and financing activities:		
Unpaid investments in oil & gas properties	677	2,723
Cost of options issued to employees attributed to oil and gas properties	077	17
cost of options issued to employees autioated to on and gas properties	-	1 /

New lease accounted for as a right of use lease asset

136

252

The accompanying notes are an integral part of the unaudited interim consolidated condensed financial statements.

Cash, cash equivalents and restricted cash, are comprised as follows:

	September 30, 2023	September 30, 2022
	US\$	US\$
	thousands	thousands
Cash and cash equivalents	510	3,079
Restricted cash included in fixed short-term bank deposits	1,020	1,294
	1,530	4,373

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 1 - Nature of Operations, Basis of Presentation and Going Concern

#### A. Nature of Operations

Zion Oil & Gas, Inc., a Delaware corporation ("we," "our," "Zion" or the "Company") is an oil and gas exploration company with a history of 23 years of oil & gas exploration in Israel. As of September 30, 2023, the Company has no revenues from its oil and gas operations.

Zion maintains its corporate headquarters in Dallas, Texas. The Company also has branch offices in Caesarea, Israel and Geneva, Switzerland. The purpose of the Israel branch is to support the Company's operations in Israel, and the purpose of the Switzerland branch is to operate a foreign treasury center for the Company.

On January 24, 2020, Zion incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts, and on January 31, 2020, Zion incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When Zion is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect.

Zion has the trademark "ZION DRILLING" filed with the United States Patent and Trademark Office. Zion has the trademark filed with the World Intellectual Property Organization in Geneva, Switzerland, pursuant to the Madrid Agreement and Protocol. In addition, Zion has the trademark filed with the Israeli Trademark Office in Israel.

#### **Exploration Rights/Exploration Activities**

#### New Megiddo Valleys License 434 ("NMVL 434")

The New Megiddo License 428 ("NML 428") was initially awarded on December 3, 2020 for a six-month term and was extended several times before expiring on February 1, 2023. Zion Oil & Gas, Inc. filed an amended application with the Israel Ministry of Energy for a new exploratory license on January 24, 2023 covering the same area as its License No. 428, which expired on February 1, 2023. However, its original application to replace License No. 428 was filed on May 11, 2022, and a revised application was filed on August 29, 2022.

On September 14, 2023, the Israel Ministry of Energy approved a new Megiddo Valleys License 434 ("NMVL 434"), allowing for oil and gas exploration on approximately 75,000 acres or 302 square kilometers. This Exploration License 434 will be valid for three years until September 13, 2026 with four 1-year extensions for a total of seven years until September 13, 2030. This NMVL 434 effectively supersedes our previous NML 428.

We continue our exploration focus here based on our studies as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential.

Zion is deploying new technologies, focusing on new stimulation methods for MJ-01, and aiming to potentially unlock hydrocarbon flows in several identified key zones. Zion has already procured service contractors and ancillary items required for efficient operations. Zion must receive approval of its work plan from the Ministry of Energy prior to commencing its re-completion activities. Zion's planned activities are currently suspended as a result of the Israel-Hamas war (See Subsequent Events for further insight).

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 1 - Nature of Operations, Basis of Presentation and Going Concern (cont'd)

#### **B.** Basis of Presentation

The accompanying unaudited interim consolidated condensed financial statements of Zion Oil & Gas, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and with Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring accruals necessary for a fair statement of financial position, results of operations and cash flows, have been included. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the operating results for the year ending December 31, 2023 or for any other subsequent interim period.

#### C. Going Concern

The Company incurs cash outflows from operations, and all exploration activities and overhead expenses to date have been financed by way of equity or debt financing. The recoverability of the costs incurred to date is uncertain and dependent upon achieving significant commercial production of hydrocarbons.

The Company's ability to continue as a going concern is dependent upon obtaining the necessary financing to undertake further exploration and development activities and ultimately generating profitable operations from its oil and natural gas interests in the future. While the Company is still actively engaging service providers in planning activities for the re-completion of the MJ-01 well, our activities are temporarily suspended due to the Israel-Hamas war. War was declared by Israel on Hamas following the October 7, 2023 invasion by Hamas in southern Israel. It is not known how long this war will last and, therefore, we cannot predict with certainty when our exploration activities will resume. The Company's current operations are dependent upon the adequacy of its current assets to meet its current expenditure requirements and the accuracy of management's estimates of those requirements. Should those estimates be materially incorrect, the Company's ability to continue as a going concern may be impaired. The consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. During the nine months ended September 30, 2023, the Company incurred a net loss of approximately \$6.2 million and had an accumulated deficit of approximately \$285 million. These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the date the financials were issued.

To carry out planned operations, the Company must raise additional funds through additional equity and/or debt issuances or through profitable operations. There can be no assurance that this capital or positive operational income will be available to the Company, and if it is not, the Company may be forced to curtail or cease exploration and development activities. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 2 - Summary of Significant Accounting Policies

#### A. Net Loss per Share Data

Basic and diluted net loss per share of common stock, par value \$0.01 per share ("Common Stock") is presented in conformity with ASC 260-10 "Earnings Per Share." Diluted net loss per share is the same as basic net loss per share as the inclusion of 53,556,910 and 56,438,572 and 53,985,877 and 41,395,169 Common Stock equivalents in the three and nine-month period ended September 30, 2023 and 2022 respectively, would be anti-dilutive.

#### **B.** Use of Estimates

The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases accounting and legal contingencies. These estimates and assumptions are based on management's best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, regional hostilities and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic and operating environment will be reflected in the consolidated financial statements in future periods.

See comments in our Subsequent Events for the impact of the Israel-Hamas war on our business and future operations.

#### C. Oil and Gas Properties and Impairment

The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized.

All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### **Note 2 - Summary of Significant Accounting Policies** (cont'd)

The Company's oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information.

During the fourth quarter of 2022, the Company testing protocol was concluded at the MJ-02 well. The test results confirmed that the MJ-02 well did not contain hydrocarbons in commercial quantities in the zones tested. As a result, in the year ended December 31, 2022, the Company recorded a non-cash impairment charge to its unproved oil and gas properties of \$45,615,000.

During the three and nine months ended September 30, 2023, the Company recorded post-impairment charges of \$36,000 and \$129,000, respectively. During the three and nine months ended September 30, 2022, the Company did not record any post-impairment charges.

Currently, the Company has no economically recoverable reserves and no amortization base. The Company's unproved oil and gas properties consist of capitalized exploration costs of \$16,342,000 and \$15,889,000 as of September 30, 2023 and December 31, 2022, respectively.

#### **D.** Fair Value Measurements

The Company follows Accounting Standards Codification (ASC) 820, "Fair Value Measurements and Disclosures," as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company's financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

- Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;
- Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and
- Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

The Company's financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At September 30, 2023, and December 31, 2022, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments.



#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 2 - Summary of Significant Accounting Policies (cont'd)

#### E. Stock-Based Compensation

ASC 718, "Compensation – Stock Compensation," prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 718 Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of the performance commitment date or performance completion date.

### F. Warrants

In connection with the Dividend Reinvestment and Stock Purchase Plan ("DSPP") financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, *Stockholders' Equity*.

#### G. Related parties

Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged.

Zion did not have any related party transactions for the periods covered in this report.

### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

### Note 2 - Summary of Significant Accounting Policies (cont'd)

#### **H. Recently Adopted Accounting Pronouncements**

In March 2020, the FASB issued ASU 2020-03, "Codification Improvements to Financial Instruments": The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. Zion adopted ASU 2020-03 in the first quarter of 2023. The adoption of this ASU did not have any impact on its consolidated financial statements.

In October 2021, the FASB issued ASU No. 2021-08, *Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.* The ASU requires companies to apply the definition of a performance obligation under ASC 606 to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. Zion adopted ASU 2021-08 in the first quarter of 2023. The adoption of this ASU did not have a material impact on our consolidated financial statements; the impact in future periods will be dependent upon the contract assets acquired and contract liabilities assumed in any future business combinations.

In September 2022, the FASB issued ASU No. 2022-04, *Liabilities – Supplier Finance Programs (Subtopic 405-50)*. The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a roll forward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for roll forward information, which is effective for fiscal years beginning after December 15, 2023. The adoption of this ASU did not have any impact on its consolidated financial statements.

#### Other Recent Accounting Pronouncements

The Company does not believe that the adoption of any recently issued accounting pronouncements in 2023 had a significant impact on our consolidated financial position, results of operations, or cash flow.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

### Note 2 - Summary of Significant Accounting Policies (cont'd)

#### I. Depreciation and Accounting for Drilling Rig and Related Equipment

Zion purchased an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of \$5.6 million in cash, inclusive of approximately \$540,000 allocated in spare parts and \$48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion is depreciating the rig on a straight-line basis.

Zion uses the First In First Out ("FIFO") method of accounting for the inventory of spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory of spare parts gets consumed.

It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly.

See the table below for a reconciliation of the rig-related activity during the nine months ended September 30, 2023:

### I-35 Drilling Rig & Associated Equipment:

	As of September 30, 2023			
	I-35 Drilling Rig	Rig Spare Parts	Other Drilling Assets	Total
	US\$	US\$	US\$	US\$
	thousands	thousands	thousands	thousands
December 31, 2022	5,225	619	437	6,281
Asset Additions	-	-	-	-
Asset Depreciation	(476)	-	(94)	(570)
Asset Disposals for Self-Consumption		(11)		(11)
September 30, 2023	4,749	608	343	5,700

During the nine months ended September 30, 2023 and 2022, the Company had depreciation expense of \$570,000 and \$560,000, respectively. During the three months ended September 30, 2023 and 2022, the Company had depreciation expense of \$190,000 and \$189,000, respectively. The asset disposal due to self-consumption was not material during the periods.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 3 - Stockholders' Equity

The Company's shareholders approved the amendment of the Company's Amended and Restated Certificate of Incorporation to increase the number of shares of common stock, par value \$0.01, that the Company is authorized to issue from 800,000,000 shares to 1,200,000,000 shares, effective June 7, 2023.

#### A. 2021 Omnibus Incentive Stock Option Plan

Effective June 9, 2021, the Company's shareholders authorized the adoption of the Zion Oil & Gas, Inc. 2021 Omnibus Incentive Stock Option Plan ("Omnibus Plan") for employees, directors and consultants, initially reserving for issuance thereunder 38,000,000 shares of common stock.

The Omnibus Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, bonus stock, awards in lieu of cash obligations, other stock-based awards and performance units. The plan also permits cash payments under certain conditions.

The compensation committee of the Board of Directors (comprised of independent directors) is responsible for determining the type of award, when and to whom awards are granted, the number of shares and the terms of the awards and exercise prices. The options are exercisable for a period not to exceed ten years from the date of grant.

During the nine months ended September 30, 2023, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation:

- i. Options to purchase 175,000 shares of Common Stock to five senior officers and one staff member at an exercise price of \$0.0615 per share. The options vested upon grant and are exercisable through January 4, 2033. The fair value of the options at the date of grant amounted to approximately \$9,000.
- ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through January 4, 2033. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$1,500.
- iii. Options to purchase 25,000 shares of Common Stock to one board member, at an exercise price of \$0.07 per share. The options vested upon grant and are exercisable through June 8, 2033. The fair value of the options at the date of grant amounted to approximately \$1,500.
- iv. Options to purchase 10,000 shares of Common Stock to one staff member at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through September 1, 2033. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$600.
- v. Options to purchase 895,000 shares of Common Stock to five staff members and one senior officer at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through September 23, 2033. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$60,000.
- vi. Options to purchase 3,350,000 shares of Common Stock to four senior officers and nine staff members at an exercise price of \$0.0676 per share. The options vest on September 23, 2024 (one year from the date of grant)

and are exercisable through September 23, 2033. The fair value of the options at the date of grant amounted to approximately \$211,000, and will be recognized during the years 2023 and 2024.

- vii. Options to purchase 3,600,000 shares of Common Stock to nine board members at an exercise price of \$0.0676 per share. The options vest on September 23, 2024 (one year from the date of grant) and are exercisable through September 23, 2033. The fair value of the options at the date of grant amounted to approximately \$227,000, and will be recognized during the years 2023 and 2024.
- viii.Options to purchase 55,000 shares of Common Stock to three consultants at an exercise price of \$0.0676 per share. The options vest on September 23, 2024 (one year from the date of grant) and are exercisable through September 23, 2033. The fair value of the options at the date of grant amounted to approximately \$3,000, and will be recognized during the years 2023 and 2024.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 3 - Stockholders' Equity (cont'd)

During the nine months ended September 30, 2022, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation:

- i. Options to purchase 175,000 shares of Common Stock to six senior officers and one staff member at an exercise price of \$0.1529 per share. The options vested upon grant and are exercisable through January 4, 2032. The fair value of the options at the date of grant amounted to approximately \$22,000.
- ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through January 4, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$4,000.
- Options to purchase 300,000 shares of Common Stock to one senior officer and one staff member at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$39,000.
- iv. Options to purchase 200,000 shares of Common Stock to one board member at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$29,000.
- v. Options to purchase 1,600,000 shares of Common Stock to five senior officers and four staff members at an exercise price of \$0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately \$209,000, and will be recognized during the years 2022 and 2023.
- vi. Options to purchase 1,400,000 shares of Common Stock to seven board members, at an exercise price of \$0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately \$182,000, and will be recognized during the years 2022 and 2023.
- vii. Options to purchase 160,000 shares of Common Stock to four staff members, at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through January 17, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$23,000.
- viii. Options to purchase 200,000 shares of Common Stock to six staff members at an exercise price of \$0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately \$26,000, and will be recognized during the years 2022 and 2023.
- ix. Options to purchase 40,000 shares of Common Stock to two consultants at an exercise price of \$0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately \$5,000, and will be recognized during the years 2022 and 2023.



#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

Note 3 - Stockholders' Equity (cont'd)

- x. Options to purchase 25,000 shares of Common Stock to one board member, at an exercise price of \$0.11 per share. The options vested upon grant and are exercisable through April 1, 2032. The fair value of the options at the date of grant amounted to approximately \$2,000.
- xi. Options to purchase 3,210,000 shares of Common Stock to five senior officers, two consultants and ten staff members at an exercise price of \$0.15 per share. The options vested on April 15, 2023 (in one year) and are exercisable through April 15, 2032. The fair value of the options at the date of grant amounted to approximately \$394,000, and will be recognized during the years 2022 and 2023.
- xii. Options to purchase 1,090,000 shares of Common Stock to one senior officer, one board member and five staff members at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through April 15, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$149,000.
- xiii. Options to purchase 3,200,000 shares of Common Stock to eight board members at an exercise price of \$0.15 per share. The options vested on April 15, 2023 (in one year) and are exercisable through April 15, 2023. The fair value of the options at the date of grant amounted to approximately \$393,000.
- xiv. Options to purchase 25,000 shares of Common Stock to one board member, at an exercise price of \$0.2350 per share. The options vested upon grant and are exercisable through August 1, 2032. The fair value of the options at the date of grant amounted to approximately \$5,000.
- xv. Options to purchase 118,000 shares of Common Stock to two senior officers and four staff members at an exercise price of \$0.2350 per share. The options vested upon grant and are exercisable through August 12, 2032. The fair value of the options at the date of grant amounted to approximately \$29,000.
- xvi. Options to purchase 75,000 shares of Common Stock to four staff members and one consultant at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through August 12, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$13,000.
- xvii. Options to purchase 10,000 shares of Common Stock to one staff member at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through September 01, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$2,000.
- xviii.Options to purchase 2,455,000 shares of Common Stock to four senior officers and thirteen staff members at an exercise price of \$0.1797 per share. The options vest on September 23, 2023 (one year from the date of grant) and are exercisable through September 23, 2032. The fair value of the options at the date of grant amounted to approximately \$396,000, and will be recognized during the years 2022 and 2023.
- xix. Options to purchase 2,700,000 shares of Common Stock to nine board members at an exercise price of \$0.1797 per share. The options vest on September 23, 2023 (one year from the date of grant) and are exercisable through September 23, 2023. The fair value of the options at the date of grant amounted to approximately \$436,000, and will be recognized during the years 2022 and 2023.

xx. Options to purchase 845,000 shares of Common Stock to one senior officer, one board member and four staff members at an exercise price of \$0.01 per share. The options vested upon grant and are exercisable through September 23, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately \$149,000.

## Consolidated Condensed Notes to Financial Statements (Unaudited)

## Note 3 - Stockholders' Equity (cont'd)

## **B. Stock Options**

The stock option transactions since January 1, 2023 are shown in the table below:

	Number of shares	Weighted Average exercise price
		US\$
Outstanding, December 31, 2022	26,391,250	0.30
Changes during 2023 to:		
Granted to employees, officers, directors and others	8,135,000	0.07
Expired/Cancelled/Forfeited	(275,000)	1.71
Exercised	(150,000)	0.07
Outstanding, September 30, 2023	34,101,250	0.23
Exercisable, September 30, 2023	27,096,250	0.27

## Consolidated Condensed Notes to Financial Statements (Unaudited)

**Note 3 - Stockholders' Equity** (cont'd)

The following table summarizes information about stock options outstanding as of September 30, 2023:

Shares und	erlying outstar	ding options (	non-vested)	Shares und	erlying outstan	ding options (f	ully vested)
Range of exercise price	Number outstanding	Weighted average remaining contractual life (years)	Weighted Average Exercise price	Range of exercise price	Number Outstanding	Weighted average remaining contractual life (years)	Weighted Average Exercise price
US\$	outstanding	me (years)	US\$	US\$	Outstanding	me (years)	
0.07	7,005,000	9.99	0.07	0.01	10,000	0.12	US\$ 0.01
0.07	7,005,000	2.33	0.07	0.01	5,000	0.12	0.01
				0.01	20,000	2.68	0.01
	_			0.01	130,000	3.26	0.01
				0.01	50,000	3.20	0.01
_				0.01	60,000	3.55	0.01
				0.01	200,000	3.64	0.01
_				0.01	40,000	4.01	0.01
				0.01	70,000	4.26	0.01
		—	—	0.01	25,000	4.27	0.01
				0.01	30,000	4.42	0.01
				0.01	4,000	4.52	0.01
	—	—		0.01	25,000	5.27	0.01
	—			0.01	35,000	5.97	0.01
	—	—	—	0.01	150,000	6.14	0.01
				0.01	35,000	6.27	0.01
	—			0.01	75,000	7.27	0.01
		—	—	0.01	200,000	7.64	0.01
	—	—		0.01	300,000	7.80	0.01
				0.01	10,000	7.93	0.01
_	—	—	—	0.01	500,000	8.27	0.01
				0.01	55,000	8.30	0.01
_	—	—	—	0.01	960,000	8.55	0.01
_				0.01	75,000	8.87	0.01
	—	—	—	0.01	10,000	8.93	0.01
_	—			0.01 0.01	795,000 25,000	8.99 9.27	0.01
_				0.01	10,000	9.27	0.01
_				0.01	895,000	9.93	0.01
				0.01	50,000	9.99	0.06
_				0.00	25,000	9.70	0.00
_	_	_		0.07	240,000	8.31	0.14
				0.15	3,200,000	8.27	0.15
_	_	_		0.15	6,410,000	8.55	0.15
				0.15	340,000	2.20	0.16
		_		0.16	75,000	6.20	0.16
	_	—		0.18	25,000	2.18	0.18

				a · -			a · -
	—		_	0.18	5,155,000	8.99	0.18
	_	—	—	0.24	25,000	8.84	0.24
	_		_	0.24	118,000	8.87	0.24
	_		_	0.25	50,000	7.93	0.25
	_		_	0.25	363,000	7.93	0.25
	—	—	—	0.28	25,000	1.93	0.28
	_		_	0.28	25,000	5.93	0.28
	_			0.29	25,000	3.71	0.29
	_		_	0.39	1,435,000	7.78	0.39
	_		_	0.59	1,400,000	3.64	0.59
—	_	—	—	0.59	1,600,000	7.64	0.59
			—	0.92	350,000	3.27	0.92
—	—	—	—	0.92	550,000	7.27	0.92
	_	—	—	1.38	105,307	1.26	1.38
—	—	—	—	1.67	405,943	1.01	1.67
			—	1.78	25,000	0.93	1.78
—	—	—	—	2.31	250,000	0.25	2.31
				4.15	25,000	0.76	4.15
0.07	7,005,000		0.07	0.01-4.15	27,096,250		0.27
				18			
				18			

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

### Note 3 - Stockholders' Equity (cont'd)

#### Granted to employees

The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants:

	nine mon	the ths ended lber 30,
	2023	2022
Weighted-average fair value of underlying stock at grant date	\$ 0.07	\$ 0.16
Dividend yields	_	_
	135%-	127%-
Expected volatility	137%	<b>6</b> 135%
	3.85%-	1.37%-
Risk-free interest rates	4.61%	<b>6</b> 3.96%
Expected lives (in years)	5.00-5.50	5.00-5.50
Weighted-average grant date fair value	\$ 0.06	\$ 0.14

### Granted to non-employees

The following table sets forth information about the weighted-average fair value of options granted to non-employees during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants:

	For the nine months ended September 30,	
	2023	2022
Weighted-average fair value of underlying stock at grant date	0.07	\$ 0.16
Dividend yields		_
Expected volatility	134%	103% - 104%
Risk-free interest rates	4.61%	1.78% - 2.84%
Expected lives (in years)	10	10
Weighted-average grant date fair value	0.06	\$ 0.15

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the options.

The expected life represents the weighted average period of time that options granted are expected to be outstanding. The expected life of the options granted to employees and directors is calculated based on the Simplified Method as allowed under Staff Accounting Bulletin No. 110 ("SAB 110"), giving consideration to the contractual term of the options and their vesting schedules, as the Company does not have sufficient historical exercise data at this time. The expected life of the option granted to non-employees equals their contractual term. In the case of an extension of the option life, the calculation was made on the basis of the extended life.

### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

## Note 3 - Stockholders' Equity (cont'd)

### C. Compensation Cost for Warrant and Option Issuances

The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors:

2023	2022
US\$ thousands	US\$ thousands
264	510
For the nine months e	nded September 30,
2023	2022
US\$ thousands	US\$ thousands
921	1,142
he following table sets forth information about the comported on the comported on the sets for the set of the	ended September 30,
he following table sets forth information about the comport non-employees:	
he following table sets forth information about the comported on the comported on the sets for the set of the	ended September 30,
he following table sets forth information about the composition of the three months e For the three months e 2023	ended September 30, 2022 US\$ thousands
he following table sets forth information about the composition of the three months e For the three months e 2023	ended September 30, 2022 US\$ thousands 8
he following table sets forth information about the comport r non-employees: For the three months e 2023 US\$ thousands	ended September 30, 2022 US\$ thousands 8
he following table sets forth information about the comport r non-employees: For the three months e 2023 US\$ thousands For the nine months en	ended September 30, 2022 US\$ thousands 8 nded September 30,

For the three months e	ended September 30,
2023	2022
US\$ thousands	US\$ thousands
—	-
For the nine months en	nded September 30,
For the nine months end 2023	nded September 30, 2022
	• •

The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties:

As of September 30, 2023, there was \$431,000 of unrecognized compensation cost related to non-vested stock options granted under the Company's various stock option plans. That cost is expected to be recognized during the remaining periods of 2023 and 2024.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 3 - Stockholders' Equity (cont'd)

#### D. Dividend Reinvestment and Stock Purchase Plan ("DSPP")

On March 13, 2014 Zion filed a registration statement on Form S-3 that was part of a replacement registration statement that was filed with the SEC using a "shelf" registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336.

On March 27, 2014, we launched our Dividend Reinvestment and Stock Purchase Plan (the "DSPP") pursuant to which stockholders and interested investors can purchase shares of the Company's Common Stock as well as units of the Company's securities directly from the Company. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the "Original Prospectus Supplement") with the Securities and Exchange Commission ("SEC") under the Company's effective registration Statement on Form S-3, as thereafter amended.

On January 13, 2015, the Company amended the Original Prospectus Supplement ("Amendment No. 3") to provide for a unit option (the "Unit Option") under the DSPP comprised of one share of Common Stock and three Common Stock purchase warrants with each unit priced at \$4.00. Each warrant afforded the participant the opportunity to purchase the Company's Common Stock at a warrant exercise price of \$1.00. Each of the three warrants series had different expiration dates that had been extended.

The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of \$1.00.

As of May 2, 2017, any outstanding ZNWAB warrants expired.

As of May 2, 2018, any outstanding ZNWAC warrants expired.

On May 29, 2019, the Company extended the termination date of the ZNWAD Warrant by one (1) year from the expiration date of May 2, 2020 to May 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

As of May 2, 2023, any outstanding ZNWAD warrants expired.

On November 1, 2016, the Company launched a unit offering under the Company's DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of \$10. The warrant is referred to as "ZNWAE."

The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of \$1.00.

On May 29, 2019, the Company extended the termination date of the ZNWAE Warrant by one (1) year from the expiration date of May 1, 2020 to May 1, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

Note 3 - Stockholders' Equity (cont'd)

As of May 1, 2023, any outstanding ZNWAE warrants expired.

On May 22, 2017, the Company launched a new unit offering. This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit offering terminated on July 12, 2017. This program enabled participants to purchase Units of the Company's securities where each Unit (priced at \$250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing \$250.00 (the price of one Unit) by the average of the high and low sale prices of the Company's Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of \$1.00 per share. The warrant is referred to as "ZNWAF."

All ZNWAF warrants became exercisable on August 14, 2017 and continued to be exercisable through August 14, 2020 at a per share exercise price of \$1.00.

On May 29, 2019, the Company extended the termination date of the ZNWAF Warrant by one (1) year from the expiration date of August 14, 2020 to August 14, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

As of August 14, 2023, any outstanding ZNWAF warrants expired.

An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017.

Under Amendment No. 2, the Company initiated another unit offering which terminated on December 6, 2017. This unit offering enabled participants to purchase Units of the Company's securities where each Unit (priced at \$250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing \$250.00 (the price of one Unit) by the average of the high and low sale prices of the Company's Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of \$1.00 per share. The warrant is referred to as "ZNWAG."

The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2023 at a revised per share exercise price of \$.25. The warrant terms provide that if the Company's Common Stock trades above \$5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 3 - Stockholders' Equity (cont'd)

On December 14, 2022, the Company extended the termination date of the ZNWAG warrant by one (1) year from the expiration date of January 8, 2023 to January 8, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at \$250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor's Plan account was credited with the number of shares of the Company's Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of \$5.00. The warrant is referred to as "ZNWAH."

The warrants became exercisable on April 2, 2018 and continued to be exercisable through April 2, 2020 at a per share exercise price of \$5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 2, 2019 to April 2, 2020.

On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 2, 2020 to April 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 2, 2021 to April 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

As of April 2, 2023, any outstanding ZNWAH warrants expired.

On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company's securities where each Unit (priced at \$250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing \$250.00 (the price of one Unit) by the average of the high and low sale prices of the Company's publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor's Plan account was credited with the number of shares of the Company's Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of \$1.00. The warrant is referred to as "ZNWAJ."

The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of \$1.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of October 29, 2019 to October 29, 2020.

On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.
On December 10, 2018, the Company initiated another unit offering, and it terminated on January 23, 2019. The offering consisted of Units of the Company's securities where each Unit (priced at \$250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of \$0.01. The investor's Plan account was credited with the number of shares of the Company's Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$0.01. The warrant is referred to as "ZNWAK."

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 3 - Stockholders' Equity (cont'd)

The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of \$0.01.

On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

As of February 25, 2023, any outstanding ZNWAK warrants expired.

On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering.

The unit offering consisted of Units of the Company's securities where each Unit (priced at \$250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of \$2.00. The investor's Plan account was credited with the number of shares of the Company's Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments ("AMI") program at a minimum of \$50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of \$2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$2.00. The warrant is referred to as "ZNWAL."

The warrants became exercisable on August 26, 2019 and continued to be exercisable through August 26, 2021 at a per share exercise price of \$2.00.

On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

As of August 26, 2023, any outstanding ZNWAL warrants expired.

Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant's Plan account was credited with the number of shares of the Company's Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$1.00. The warrant shall have the company notation of "ZNWAM." The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continued to be exercisable through July 15, 2022.

On March 21, 2022, the Company extended the termination date of the ZNWAM warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023 and revised the exercise price to \$0.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On June 16, 2023, the Company extended the termination date of the ZNWAM warrant from July 15, 2023 to September 6, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On August 21, 2023, the Company extended the termination date of the ZNWAM warrant from September 6, 2023 to October 31, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On October 19, 2023, the Company extended the termination date of the ZNWAM warrant from October 31, 2023 to December 31, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

Note 3 - Stockholders' Equity (cont'd)

The unit offering consisted of Units of the Company's securities where each Unit (priced at \$250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of \$1.00. The investor's Plan account was credited with the number of shares of the Company's Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments ("AMI") program at a minimum of \$50.00 per month or more, received an additional ten (10) warrants at an exercise price of \$1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$1.00. The warrant is referred to as "ZNWAN."

The warrants became exercisable on May 16, 2021 and continued to be exercisable through May 16, 2023 at a per share exercise price of \$1.00.

As of May 16, 2023, any outstanding ZNWAN warrants expired.

On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021.

The unit offering consisted of Units of the Company's securities where each Unit (priced at \$250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of \$.25. The investor's Plan account was credited with the number of shares of the Company's Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments ("AMI") program at a minimum of \$50.00 per month or more, received an additional fifty (50) warrants at an exercise price of \$.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$.25. The warrant is referred to as "ZNWAO."

The warrants became exercisable on June 12, 2021 and continued to be exercisable through June 12, 2023 at a per share exercise price of \$.25.

As of June 12, 2023, any outstanding ZNWAO warrants expired.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant's Plan account was credited with the number of shares of the Company's Common Stock that were acquired.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant's Plan account was credited with the number of shares of the Company's Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$.25. The warrant shall have the company notation of "ZNWAQ." The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued on May 5, 2022 and were exercisable through July 15, 2023 at a revised per share exercise price of \$.05.



#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 3 - Stockholders' Equity (cont'd)

Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On June 16, 2023, the Company extended the termination date of the ZNWAQ warrant from July 15, 2023 to September 6, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On August 21, 2023, the Company extended the termination date of the ZNWAQ warrant from September 6, 2023 to October 31, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

On October 19, 2023, the Company extended the termination date of the ZNWAQ warrant from October 31, 2023 to December 31, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant's Plan account was credited with the number of shares of the Company's Common Stock that were acquired.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on November 15, 2021, the participant's Plan account was credited with the number of shares of the Company's Common Stock and warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$1.00. The warrant shall have the company notation of "ZNWAS." The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a revised per share exercise price of \$.25.

On December 9, 2019 Zion filed an Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-235299) solely for the purpose of re-filing a revised Exhibit 5.1 to the Registration Statement. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly, such prospectus has not been included herein.

On December 10, 2021 Zion filed an Amendment No. 1 to the Registration Statement on Form S-3 (File No. 333-235299) for the purpose of converting the existing Form S-1 to the Registration Statement on Form S-3. This Amendment No. 1 does not modify any provision of the prospectus that forms a part of the Registration Statement and accordingly such prospectus has not been included herein.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on September 30, 2022, the participant's Plan account was credited with the number of shares of the Company's Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$.25. The warrant shall have the company notation of "ZNWAT." The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of \$.25.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on December 31, 2022, the participant's Plan account was credited with the number of shares of the Company's Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$.25. The warrant shall have the company notation of "ZNWAU." The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of \$.25.

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a program consisting of shares of stock to a participant. After conclusion of the program on August 31, 2023, the participant's Plan account was credited with the number of shares of the Company's Common Stock that were acquired. Zion incurred \$173,000 in equity issuance costs to an outside party related to this waiver program. The Company executed two additional Waiver Term Sheets with the same participant consisting of shares of stock. After conclusion of the program on December 31, 2023, the participant's Plan account will be credited with the number of shares of the Company's Common Stock that were acquired. During the quarter ended September 30, 2023, Zion incurred an additional \$437,000 in equity issuance costs bringing the YTD total to approximately \$610,000.

On March 13, 2023, Zion filed with the Securities and Exchange Commission an Amendment No. 2 to the Prospectus Supplement dated as of December 15, 2021 and accompanying base prospectus dated December 1, 2021 relating to the Company's Dividend Reinvestment and Direct Stock Purchase Plan. This Amendment No. 2 to Prospectus Supplement amended the Prospectus Supplement. The Prospectus forms a part of the Company's Registration Statement on Form S-3 (File No. 333-261452), as amended, which was declared effective by the SEC on December 15, 2021.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

### Note 3 - Stockholders' Equity (cont'd)

#### Amendment No. 2 - New Unit Option under the Unit Program

Under our Plan, we provided a Unit Option under Amendment No. 2. Our Unit Program consisted of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1. Amendment No. 2 provided the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. This Unit Option had up to three tranches of investment, in which the second and third tranches were each subject to termination upon a total of \$7,500,000 received from participants by the Company during the first or second tranche. The first tranche period began on March 13, 2023 and terminated on March 26, 2023. The second tranche began on March 27, 2023 and terminated on April 9, 2023 and the third tranche began on April 10, 2023 and terminated on April 27, 2023.

The Unit Option consisted of Units of our securities where each Unit (priced at \$250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing \$250.00 (the price of one Unit) by the average of the high and low sale prices of the Company's publicly traded common stock as reported on the OTCQX on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional five hundred (500) shares of Common Stock at a per share exercise price of \$0.05. The participant's Plan account was credited with the number of shares of the Company's Common Stock and Warrants that were acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$0.05. The warrant shall have the Company notation of "ZNWAV" under the first tranche, "ZNWAW" under the second tranche and "ZNWAX" under the third tranche.

Plan participants, who enrolled into the Unit Program with the purchase of at least one Unit and enrolled in the separate Automatic Monthly Investments ("AMI") program at a minimum of \$50.00 per month, received an additional fifty (50) warrants at an exercise price of \$0.05 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program and shall have the Company notation of "ZNWAY." Existing subscribers to the AMI were entitled to the additional fifty (50) warrants, if they purchased at least one (1) Unit during the Unit program. Plan participants, who enrolled in the AMI at a minimum of \$100 per month, received one hundred (100) ZNWAY warrants. Plan participants, who enrolled in the AMI at a minimum of \$250 per month, received two hundred and fifty (250) ZNWAY warrants. Plan participants, who enrolled in the AMI at a minimum of \$250 per month, received two hundred and fifty (250) ZNWAY warrants. The AMI program required 90 days of participation to receive the ZNWAY warrants. Existing AMI participants were entitled to participate in this monthly program by increasing their monthly amount above the minimum \$50.00 per month.

The ZNWAV warrants became exercisable on March 31, 2023 and continued to be exercisable through June 28, 2023 at a per share exercise price of \$0.05.

As of June 28, 2023, any outstanding ZNWAV warrants expired.

The ZNWAW warrants became exercisable on April 14, 2023 and continued to be exercisable through July 13, 2023 at a per share exercise price of \$0.05.

As of July 13, 2023, any outstanding ZNWAW warrants expired.

The ZNWAX warrants became exercisable on May 2, 2023 and continued to be exercisable through July 31, 2023 at a per share exercise price of \$0.05.

On July 31, 2023, any outstanding ZNWAX warrants expired.

The ZNWAY warrants became exercisable on June 12, 2023 and continued to be exercisable through September 10, 2023 at a per share exercise price of \$0.05.

On September 10, 2023, any outstanding ZNWAY warrants expired.

Amendment No. 3 – New Unit Option under the Unit Program

Under our Plan, provided a Unit Option under Amendment No. 3. This Unit Option period began on May 15, 2023 and terminated on June 15, 2023.

Our Unit Program consisted of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1 and Amendment No.2. Amendment No. 3 provided the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. As mentioned above, this Unit Option began on May 15, 2023 and terminated on June 15, 2023. The Unit Option consisted of Units of our securities where each Unit (priced at \$250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing \$250.00 (the price of one Unit) by the average of the high and low sale prices of the Company's publicly traded common stock as reported on the OTCQX on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional two hundred (200) shares of Common Stock at a per share exercise price of \$0.25. The participant's Plan account was credited with the number of shares of the Company notation of "ZNWAZ" and will not be registered for trading on the OTCQX or any other stock market or trading market.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 3 - Stockholders' Equity (cont'd)

Plan participants, who enrolled into the Unit Program with the purchase of at least one Unit and enrolled in the separate Automatic Monthly Investments ("AMI") program at a minimum of \$50.00 per month, received an additional three hundred (300) warrants at an exercise price of \$0.25 during this Unit Option Program. The three hundred (300) additional warrants were for enrolling into the AMI program and received the above warrant with the Company notation of "ZNWAZ." Existing subscribers to the AMI were entitled to the additional three hundred (300) warrants, if they purchased at least one (1) Unit during the Unit program.

The ZNWAZ warrants became exercisable on July 17, 2023 and continue to be exercisable through July 17, 2024 at a per share exercise price of \$0.25.

#### Amendment No. 4 – New Unit Option under the Unit Program

Under our Plan, we are providing a Unit Option under our Unit Program with this Amendment No. 4. This Unit Option period began on November 6, 2023 and terminates on December 31, 2023.

Our Unit Program consists of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1. Amendment No. 4 provides the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. This Unit Option began on November 6, 2023 and is scheduled to terminate on December 31, 2023, unless extended at the sole discretion of Zion Oil & Gas, Inc. The Unit Option consists of Units of our securities where each Unit (priced at \$250.00 each) is comprised of (i) a certain number of shares of Common Stock determined by dividing \$250.00 (the price of one Unit) by the average of the high and low sale prices of the Company's publicly traded common stock as reported on the OTCQX on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of \$0.25. The participant's Plan account will be credited with the number of shares of the Company's Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of \$0.25. The warrant shall have the Company notation of "ZNWBA" and will not be registered for trading on the OTCQX or any other stock market or trading market.

Plan participants, who enroll into the Unit Program with the purchase of at least one Unit and enroll in the separate Automatic Monthly Investments ("AMI") program at a minimum of \$50.00 per month, will receive an additional fifty (50) warrants at an exercise price of \$0.25 during this Unit Option Program. The fifty (50) additional warrants are for enrolling into the AMI program and shall receive the above warrant with the Company notation of "ZNWBA." Existing subscribers to the AMI are entitled to the additional fifty (50) warrants, if they purchase at least one (1) Unit during the Unit program.

The ZNWBA warrants will become exercisable on January 15, 2024, unless extended, and continue to be exercisable through January 14, 2025, unless extended, at a per share exercise price of \$0.25.

For the three and nine months ended September 30, 2023, approximately \$1,805,000, and \$4,358,000 were raised under the DSPP program, respectively. The \$4,358,000 figure is net of \$610,000 in equity issuance costs to an outside party.

For the three and nine months ended September 30, 2022, approximately \$3,477,000, and \$16,470,000 were raised under the DSPP program, respectively.

The company raised approximately \$391,000 from the period October 1, 2023 through November 7, 2023, under the DSPP program.

The warrants represented by the company notation ZNWAA are tradeable on the OTCQX market under the symbol ZNOGW. However, all of the other warrants characterized above, in the table below, and throughout this Form 10-Q, are not tradeable and are used internally for classification and accounting purposes only.

# Consolidated Condensed Notes to Financial Statements (Unaudited)

Note 3 - Stockholders' Equity (cont'd)

### E. Warrant Table

The warrants balances at December 31, 2022 and transactions since January 1, 2023 are shown in the table below:

Warrants	ercise Price	Warrant Termination Date	Outstanding Balance, 12/31/2022	Warrants Issued	Warrants Exercised	Warrants Expired	Outstanding Balance, 9/30/2023
ZNWAA	\$ 2.00	01/31/2024	1,498,804	-	-	-	1,498,804
ZNWAD	\$ 1.00	05/02/2023	243,853	-	-	(243,853)	-
ZNWAE	\$ 1.00	05/01/2023	2,144,099	-	-	(2,144,099)	-
ZNWAF	\$ 1.00	08/14/2023	359,435	-	-	(359,435)	-
ZNWAG	\$ 1.00	01/08/2024	240,068	-	-	-	240,068
ZNWAH	\$ 5.00	04/19/2023	372,400	-	-	(372,400)	-
ZNWAI	\$ 3.00	06/29/2023	640,710	-	(100)	(640,610)	-
ZNWAJ	\$ 1.00	10/29/2023	545,900	-	-	-	545,900
ZNWAK	\$ 0.01	02/25/2023	424,225	-	(9,050)	(415,175)	-
ZNWAL	\$ 2.00	08/26/2023	517,875	-	-	(517,875)	-
ZNWAM	\$ 0.05	12/31/2023	4,376,000	-	-	-	4,376,000
ZNWAN	\$ 1.00	05/16/2023	267,760	-	(75)	(267,685)	-
ZNWAO	\$ 0.25	06/12/2023	174,660	-	-	(174,660)	-
ZNWAQ	\$ 0.05	12/31/2023	23,428,348	-	-	-	23,428,348
ZNWAV	\$ 0.05	06/28/2023	-	288,500	(167,730)	(120,770)	-
ZNWAW	\$ 0.05	07/13/2023	-	199,000	(151,500)	(47,500)	-
ZNWAX	\$ 0.05	07/31/2023	-	818,500	(458,750)	(359,750)	-
ZNWAY	\$ 0.05	09/10/2023		17,450	(3,700)	(13,750)	-
ZNWAZ	\$ 0.25	07/17/2024	-	153,500		-	153,500
Outstanding							
warrants			35,234,137	1,476,950	(790,905)	(5,677,562)	30,242,620

# F. Warrant Descriptions of Current Warrants

The price and the expiration dates for the series of warrants to investors are shown in the table below. The listing contains only those warrants with an expiration date beyond the balance sheet date.

		Period of Grant	US\$	Expiration Date
ZNWAA Warrants	A,B,E	March 2013 – December 2014	2.00	January 31, 2024
ZNWAG Warrants	B,E	October 2017 – December 2017	1.00	January 08, 2024
ZNWAJ Warrants	A,B	August 2018 – September 2018	1.00	October 29, 2023
ZNWAM Warrants	C,F	January 2021 – March 2021	0.05	December 31, 2023
ZNWAQ Warrants	C,F	June 2021	0.05	December 31, 2023
ZNWAS Warrants	D	August 2021 – March 2022	0.25	December 31, 2025
ZNWAT Warrants	D	August – September 2022	0.25	December 31, 2025
ZNWAU Warrants	D	October – November 2022	0.25	December 31, 2025
ZNWAZ Warrants	G	May – June 2023	.25	July 17, 2024
ZNWBA Warrants	Н	November – December 2023	.25	January 15, 2025

A On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year.

- B On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years.
- C On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year. On June 16, 2023, the Company extended the expiration date of the Warrants to September 6, 2023. On August 21, 2023, the Company extended the expiration date of the Warrants to October 31, 2023. On October 19, 2023, the Company extended the expiration date of the Warrants to December 31, 2023.
- D These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025.
- E On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year.
- F The warrant exercise price was lowered to \$0.05 on December 28, 2022.
- G On May 15, 2023, the Company announced a new Unit Offering and the related ZNWAZ warrant.
- H On November 6, 2023 the Company announced a new Unit Offering and the related ZNWBA warrant.

# Consolidated Condensed Notes to Financial Statements (Unaudited)

# Note 4 - Unproved Oil and Gas Properties, Full Cost Method

Unproved oil and gas properties, under the full cost method, are comprised as follows:

	September 30, 2023	December 31, 2022
	US\$	US\$
	thousands	thousands
Excluded from amortization base:		
Drilling costs, and other operational related costs	2,490	2,362
Capitalized salary costs	2,419	2,342
Capitalized interest costs	1,418	1,418
Legal and seismic costs, license fees and other preparation costs	9,976	9,728
Other costs	39	39
	16,342	15,889

Post Impairment of unproved oil and gas properties are comprised as follows:

	For the three I Septem		For the nine r Septem	
	2023	2022	2023	2022
	US\$	US\$	US\$	US\$
	thousands	thousands	thousands	thousands
Excluded from amortization base:				
Drilling costs, and other operational related costs	20	-	76	-
Capitalized salary costs	-	-	-	-
Capitalized interest costs	-	-	-	-
Legal costs, license fees and other preparation costs	16	-	53	-
Other costs				-
	36		129	

Changes in Unproved oil and gas properties during the three and nine months ended September 30, 2023 and 2022 are as follows:

# For the three months ended For the nine months ended

	Septem	ber 30,	Septem	ber 30,
	2023	2022	2023	2022
	US\$	US\$	US\$	US\$
	thousands	thousands	thousands	thousands
Excluded from amortization base:				
Drilling costs, and other operational related costs	58	5,350	204	10,666
Capitalized salary costs	25	30	77	151
Capitalized interest costs	-	-	-	-
Legal costs, license fees and other preparation costs	103	586	301	1,402
Other costs	-	-	-	-
Impairment of unproved oil and gas properties	(36)		(129)	

*150	*5,966	*453	*12,219

- \* Inclusive of non-cash amounts of approximately \$129,000, and \$1,032,000 during the three months ended September 30, 2023, and 2022, respectively
- \* Inclusive of non-cash amounts of approximately \$677,000, and \$2,740,000 during the nine months ended September 30, 2023, and 2022, respectively

 $Please \ refer \ to \ Footnote \ 1-Nature \ of \ Operations \ and \ Going \ Concern \ for \ more \ information \ about \ Zion's \ exploration \ activities.$ 

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

### Note 5 - Right of use lease assets and lease obligations

The Company is a lessee in several non-cancellable operating leases for transportation and office space.

The table below presents the operating lease assets and liabilities recognized on the balance sheet as of September 30, 2023 and December 31, 2022:

	Sep	tember 30, 2023	De	ecember 31, 2022
	tł	US\$ housands	t	US\$ thousands
Operating lease assets	\$	246	\$	202
Operating lease liabilities:				
Current operating lease liabilities	\$	192	\$	196
Non-current operating lease liabilities	\$	53	\$	12
Total operating lease liabilities	\$	245	\$	208

The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term.

The Company's leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date.

The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of September 30, 2023 are:

	September 30, 2023
Weighted average remaining lease term (years)	1.08
Weighted average discount rate	5.9%

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

### Note 5 - Right of use lease assets and leases obligations (cont'd)

The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed balance sheets as of September 30, 2023:

	US\$
	thousands
2023	75
2024	178
2025	-
2026	-
Thereafter	
Total undiscounted future minimum lease payments	253
Less: portion representing imputed interest	(8)
Total undiscounted future minimum lease payments	245

#### \* Less than one thousand.

Operating lease costs were \$76,000 and \$203,000 for the three and nine months ended September 30, 2023, respectively. Operating lease costs are included within general and administrative expenses on the statements of operations.

Operating lease costs were \$69,000 and \$206,000 for the three and nine months ended September 30, 2022, respectively. Operating lease costs are included within general and administrative expenses on the statements of operations.

Cash paid for amounts included in the measurement of operating lease liabilities was \$76,000 and \$203,000 for the three and nine months ended September 30, 2023, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was \$71,000 and \$214,000 for the three and nine months ended September 30, 2022, respectively. These amounts are included in operating activities in the statements of cash flows.

Right-of-use assets obtained in exchange for new operating lease liabilities were \$252,000 and \$252,000 for the three and nine months ended September 30, 2023, respectively.

Right-of-use assets obtained in exchange for new operating lease liabilities were \$nil and \$136,000 for the three and nine months ended September 30, 2022, respectively.



#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 6 - Commitments and Contingencies

#### A. Securities and Exchange Commission ("SEC") Investigation

As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation, which we did.

On April 5, 2023, the Company received from the Fort Worth Regional Office of the SEC written notice to the Company concluding the investigation as to the Company and that the SEC does "not intend to recommend an enforcement action by the Commission against Zion."

#### **B.** Litigation

From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes.

The Company is not subject to any litigation at the present time.

### C. Market Conditions – Coronavirus Pandemic and Israel-Hamas War

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus ("COVID-19"). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. However, as of the date of this report, most of our employees are working at our physical offices, but have the ability to work from home as needed.

See comments in "Subsequent Events" for the potential impact of the Israel-Hamas War on our operations.

### D. Environmental and Onshore Licensing Regulatory Matters

The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental clean-up of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel's Petroleum Commissioner and Energy and Environmental Ministries as it pertains to oil and gas activities. Mention of these older guidelines was included in previous Zion filings.

The Company believes that these regulations will result in an increase in the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that an additional financial burden could occur as a result of requiring cash reserves that could otherwise be used for operational purposes. In addition, these regulations are likely to continue to increase the time needed to obtain all of the necessary authorizations and approvals to drill and production test exploration wells.

As of September 30, 2023, and December 31, 2022, the Company accrued \$nil and \$nil for license regulatory matters.

### E. Bank Guarantees

As of September 30, 2023, the Company provided Israeli-required bank guarantees to various governmental bodies (approximately \$930,000) and others (approximately \$85,000) with respect to its drilling operation in an aggregate amount of approximately \$1,015,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts in Israel and are reported on the Company's balance sheets as fixed short-term bank deposits – restricted.

#### **Consolidated Condensed Notes to Financial Statements (Unaudited)**

#### Note 6 - Commitments and Contingencies (cont'd)

#### F. Market Risk

Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the market-related risks associated with foreign currency exchange rates and changes in interest rates.

*Foreign Currency Exchange Rate Risks.* A portion of our expenses, primarily labor expenses and certain supplier contracts, are denominated in New Israeli Shekels ("NIS"). As a result, we have significant exposure to the risk of fluctuating exchange rates with the U.S. Dollar ("USD"), our primary reporting currency. During the period January 1, 2023 through September 30, 2023, the USD has fluctuated by approximately 8.7% against the NIS (the USD strengthened relative to the NIS). Also, during the period January 1, 2022 through December 31, 2022, the USD fluctuated by approximately 13.2% against the NIS (the USD strengthened relative to the NIS). Continued strengthening of the US dollar against the NIS will result in lower operating costs from NIS denominated expenses. To date, we have not hedged any of our currency exchange rate risks, but we may do so in the future.

*Interest Rate Risk.* Our exposure to market risk relates to our cash and investments. We maintain an investment portfolio of short-term bank deposits and money market funds. The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced income in a low interest rate environment. At September 30, 2023, we had cash, cash equivalents and short-term bank deposits of approximately \$1,530,000. The weighted average annual interest rate related to our cash and cash equivalents for the three and nine months ended September 30, 2023, exclusive of funds at US banks that earn no interest, was approximately 4.45% and 3.51%, respectively.

The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

### Note 7 - Subsequent Events

- (i) On October 7, 2023, Hamas, a militant terrorist organization in Gaza, infiltrated southern Israel, killing and injuring at least one thousand Israeli citizens. This unprovoked attack led the nation of Israel to declare war on Hamas approximately one week later. As of the date of this report, Israel remains at war, which lead the Company to temporarily discontinue its exploration activities. It is currently not determinable when the resumption of our exploration activities will begin.
- (ii) Approximately \$391,000 was collected through the Company's DSPP program during the period October 1 through November 7, 2023.

# ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH OUR UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND THE RELATED NOTES TO THOSE STATEMENTS INCLUDED IN THIS FORM 10-Q. SOME OF OUR DISCUSSION IS FORWARD-LOOKING AND INVOLVES RISKS AND UNCERTAINTIES. FOR INFORMATION REGARDING RISK FACTORS THAT COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, REFER TO THE DISCUSSION OF RISK FACTORS IN THE "DESCRIPTION OF BUSINESS" SECTION OF OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2022, FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AND TO THE SUBSEQUENT EVENTS IN NOTE 7 OF THIS FORM 10-Q.

#### **Forward-Looking Statements**

Certain statements made in this discussion are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may materially differ from actual results.

Forward-looking statements can be identified by terminology such as "may", "should", "expects", "intends", "anticipates", "believes", "estimates", "predicts", or "continue" or the negative of these terms or other comparable terminology and include, without limitation, statements regarding:

- The Israel-Hamas war which began in October 2023 and its effect on our exploration program;
- the going concern qualification in our consolidated financial statements;
- our ability to obtain new license areas to continue our petroleum exploration program;
- our liquidity and our ability to raise capital to finance our overall exploration and development activities within our license area;
- our ability to continue meeting the requisite continued listing requirements by OTCQX;
- business interruptions from the COVID-19 pandemic and the Israel-Hamas war;
- interruptions, increased consolidated financial costs and other adverse impacts of the coronavirus pandemic and the Israel-Hamas war on the drilling and testing of our petroleum exploration program and our capital raising efforts;
- our ability to explore for and develop natural gas and oil resources successfully and economically within a license area;
- our ability to maintain the exploration license rights to continue our petroleum exploration program;
- the availability of equipment, such as seismic equipment, drilling rigs, and production equipment as well as access to qualified personnel;
- the impact of governmental regulations, permitting and other legal requirements in Israel relating to onshore exploratory drilling;
- our estimates of the time frame within which future exploratory activities will be undertaken;
- changes in our exploration plans and related budgets;

- the quality of existing and future license areas with regard to, among other things, the existence of hydrocarbon reserves in economic quantities;
- anticipated trends in our business;
- our future results of operations;
- our capital expenditure program;
- future market conditions in the oil and gas industry
- the demand for oil and natural gas, both locally in Israel and globally; and
- the impact of fluctuating oil and gas prices on our exploration efforts

All references in this Quarterly Report to the "Company", "Zion", "we", "us", or "our", are to Zion Oil and Gas, Inc., a Delaware corporation, and its wholly-owned subsidiaries, Zion Drilling, Inc. and Zion Drilling Services, Inc. described below.

### **Current Exploration and Operation Efforts**

Zion Oil and Gas, Inc., a Delaware corporation, is an oil and gas exploration company with a history of 23 years of oil and gas exploration in Israel. We were incorporated in Florida on April 6, 2000 and reincorporated in Delaware on July 9, 2003. We completed our initial public offering in January 2007. Our common stock, par value \$0.01 per share (the "Common Stock") currently trades on the OTCQX marketplace of OTC Markets, Inc. under the symbol "ZNOG" and our Common Stock warrant under the symbol "ZNOGW." On January 24, 2020, the Company incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts, and on January 31, 2020, the Company incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When the Company is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect.

The New Megiddo License 428 ("NML 428") was initially awarded on December 3, 2020 for a six-month term and was extended several times before expiring on February 1, 2023. Zion Oil & Gas, Inc. filed an amended application with the Israel Ministry of Energy for a new exploratory license on January 24, 2023 covering the same area as its License No. 428, which expired on February 1, 2023. However, its original application to replace License No. 428 was filed on May 11, 2022, and a revised application was filed on August 29, 2022.

On September 14, 2023, the Israel Ministry of Energy approved a new Megiddo Valleys License 434, allowing for oil and gas exploration on approximately 75,000 acres or 302 square kilometers. This Exploration License 434 will be valid for three years until September 13, 2026 with four 1-year extensions for a total of seven years until September 13, 2030. This NMVL 434 effectively supersedes our previous NML 428.

We continue our exploration focus here based on our studies as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential.

Zion is deploying new technologies, focusing on new stimulation methods for MJ-01, and aiming to potentially unlock hydrocarbon flows in several identified key zones. Zion has already procured service contractors and ancillary items required for efficient operations. Zion must receive approval of its work plan from the Ministry of Energy prior to commencing its re-completion activities. Israel declared war on Hamas in mid-October 2023 following the October 7, 2023 unprovoked attack on Israeli citizens by Hamas. Israel has formed an emergency unity government in partial response to the attack. It is not known how long this war with Hamas will continue nor any specific timetable for when Zion may resume its exploration activities.

The projected costs to perform the anticipated re-completion activities for NMVL is expected to be \$4,000,000 to \$5,000,000 and require from three to six months.

# I-35 Drilling Rig & Associated Equipment

	Nine-mon	Nine-month period ended September 30, 2023				
	I-35 Drilling Rig	Rig Spare Parts	Other Drilling Assets	Total		
	US\$ thousands	US\$ thousands	US\$ thousands	US\$ thousands		
December 31, 2022	5,225	619	437	6,281		
Asset Additions	-	-	-	-		
Asset Depreciation	(476)	-	(94)	(570)		
Asset Disposals for Self-Consumption		(11)		(11)		
September 30, 2023	4,749	608	343	5,700		

Zion's ability to fully undertake all of these aforementioned activities is subject to its raising the needed capital from its continuing offerings, of which no assurance can be provided, as well as the resumption of our activities following the war with Hamas.



Map 1. Zion's Megiddo Valleys 434 License as of September 30, 2023.

#### **Onshore Licensing, Oil and Gas Exploration and Environmental Guidelines**

The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental cleanup of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel's Petroleum Commissioner, the Energy Ministry, and the Environmental Ministry in recent years as it pertains to oil and gas activities. Mention of these guidelines was included in previous Zion Oil & Gas filings.

We acknowledge that these new regulations are likely to increase the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that additional financial burdens could occur as a result of the Ministry requiring cash reserves that could otherwise be used for operational purposes.

#### **Capital Resources Highlights**

We need to raise significant funds to finance the continued exploration efforts and maintain orderly operations. To date, we have funded our operations through the issuance of our securities and convertible debt. We will need to continue to raise funds through the issuance of equity and/or debt securities (or securities convertible into or exchangeable for equity securities). No assurance can be provided that we will be successful in raising the needed capital on terms favorable to us (or at all).

#### The Dividend Reinvestment and Stock Purchase Plan

On March 13, 2014 Zion filed a registration statement on Form S-3 that is part of a replacement registration statement that was filed with the SEC using a "shelf" registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336.

On March 27, 2014, we launched our Dividend Reinvestment and Stock Purchase Plan (the "DSPP") pursuant to which stockholders and interested investors can purchase shares of the Company's Common Stock as well as units of the Company's securities directly from the Company. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the "Original Prospectus Supplement") with the Securities and Exchange Commission ("SEC") under the Company's effective registration Statement on Form S-3, as thereafter amended.

Please see Footnote 3D ("Dividend Reinvestment and Stock Purchase Plan ("DSPP")), which is a part of this Form 10-Q filing, for details about specific stock purchase and unit programs, dates, and filings during the years 2016 through 2023.

For the three and nine months ended September 30, 2023, approximately \$1,805,000, and \$4,358,000 were raised under the DSPP program, respectively. The \$4,358,000 figure is net of \$610,000 in equity issuance costs to an outside party.

For the three and nine months ended September 30, 2022, approximately \$3,477,000, and \$16,740,000 were raised under the DSPP program, respectively.

The warrants balances at December 31, 2022 and transactions since January 1, 2023 are shown in the table below:

		Warrant	Outstanding				Outstanding
	Exercise	Termination	Balance,	Warrants	Warrants	Warrants	Balance,
Warrants	Price	Date	12/31/2022	Issued	Exercised	Expired	9/30/2023

ZNWAA	\$ 2.00	01/31/2024	1,498,804	_	_	_	1,498,804
ZNWAD	\$ 1.00	05/02/2023	243,853	-	-	(243,853)	-
ZNWAE	\$ 1.00	05/01/2023	2,144,099	-	-	(2,144,099)	-
ZNWAF	\$ 1.00	08/14/2023	359,435	-	-	(359,435)	-
ZNWAG	\$ 1.00	01/08/2024	240,068	-	-	-	240,068
ZNWAH	\$ 5.00	04/19/2023	372,400	-	-	(372,400)	-
ZNWAI	\$ 3.00	06/29/2023	640,710	-	(100)	(640,610)	-
ZNWAJ	\$ 1.00	10/29/2023	545,900	-	-	-	545,900
ZNWAK	\$ 0.01	02/25/2023	424,225	-	(9,050)	(415,175)	-
ZNWAL	\$ 2.00	08/26/2023	517,875	-	-	(517,875)	-
ZNWAM	\$ 0.05	12/31/2023	4,376,000	-	-	-	4,376,000
ZNWAN	\$ 1.00	05/16/2023	267,760	-	(75)	(267,685)	-
ZNWAO	\$ 0.25	06/12/2023	174,660	-	-	(174,660)	-
ZNWAQ	\$ 0.05	12/31/2023	23,428,348	-	-	-	23,428,348
ZNWAV	\$ 0.05	06/28/2023	-	288,500	(167,730)	(120,770)	-
ZNWAW	\$ 0.05	07/13/2023	-	199,000	(151,500)	(47,500)	-
ZNWAX	\$ 0.05	07/31/2023	-	818,500	(458,750)	(359,750)	-
ZNWAY	\$ 0.05	09/10/2023		17,450	(3,700)	(13,750)	-
ZNWAZ	\$ 0.25	07/17/2024		153,500			153,500
Outstanding warrants			35,234,137	1,476,950	(790,905)	(5,677,562)	30,242,620
			38				

#### **Principal Components of our Cost Structure**

Our operating and other expenses primarily consist of the following:

- Impairment of Unproved Oil and Gas Properties: Impairment expense is recognized if a determination
  is made that a well will not be commercially productive. The amounts include amounts paid in respect
  of the drilling operations as well as geological and geophysical costs and various amounts that were paid
  to Israeli regulatory authorities.
- General and Administrative Expenses: Overhead, including payroll and benefits for our corporate staff, costs of managing our exploratory operations, audit and other professional fees, and legal compliance is included in general and administrative expenses. General and administrative expenses also include noncash stock-based compensation expense, investor relations related expenses, lease and insurance and related expenses.
- Depreciation, Depletion, Amortization and Accretion: The systematic expensing of the capital costs incurred to explore for natural gas and oil represents a principal component of our cost structure. As a full cost company, we capitalize all costs associated with our exploration, and apportion these costs to each unit of production, if any, through depreciation, depletion and amortization expense. As we have yet to have production, the costs of abandoned wells are written off immediately versus being included in this amortization pool.

#### **Going Concern Basis**

Since we have limited capital resources, no revenue to date and a loss from operations, our consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. The appropriateness of using the going concern basis is dependent upon our ability to obtain additional financing or equity capital and, ultimately, to achieve profitable operations. Therefore, there is substantial doubt about our ability to continue as a going concern for one year from the date the financials were issued. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

### The Impact of COVID-19

During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus ("COVID-19"). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. As of the date of this report, the Company adopted a hybrid model whereby many of our employees are working from corporate office two to three days per week and then working remotely two to three days per week.

The full extent of COVID-19's impact on our operations and financial performance depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic, its impact on capital and financial markets and any new information that may emerge concerning the severity of the virus, its spread to other regions as well as the actions taken to contain it, among others.

The main area in which Zion has experienced COVID-19's impact has been in supply chain and/or logistics. We have worked with several suppliers worldwide for the procurement of oil and gas parts, inventory items and related labor for our ongoing operations for the MJ-02 well. Production delays, factory shutdowns and heavy demand by oil and gas operators worldwide for spare parts has created some challenges in obtaining these items in a timely fashion.

### The Impact of the Israel-Hamas War

Please see Part II, Item 1a for a discussion of the Israel-Hamas war and its effect on Zion's exploration program.

# **Critical Accounting Policies**

Management's discussion and analysis of financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expense during the reporting period.

We have identified the accounting principles which we believe are most critical to the reported financial status by considering accounting policies that involve the most complex of subjective decisions or assessment.

### Impairment of Oil and Gas Properties

We follow the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized.

All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in income from continuing operations before income taxes, and the adjusted carrying amount of the unproved properties is amortized on the unit-of-production method.

Our oil and gas properties represent an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. A further impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information.

Abandonment of properties is accounted for as adjustments to capitalized costs. The net capitalized costs are subject to a "ceiling test" which limits such costs to the aggregate of the estimated present value of future net revenues from proved reserves discounted at ten percent based on current economic and operating conditions, plus the lower of cost or fair market value of unproved properties. The recoverability of amounts capitalized for oil and gas properties is dependent upon the identification of economically recoverable reserves, together with obtaining the necessary financing to exploit such reserves and the achievement of profitable operations.

During the three months ended September 30, 2023, and 2022, respectively, the Company recorded \$36,000 and nil post-impairment charges.

During the nine months ended September 30, 2023, and 2022, respectively, the Company recorded \$129,000 and nil post-impairment charges.

The total net book value of our unproved oil and gas properties under the full cost method is \$16,342,000 and \$15,889,000 at September 30, 2023 and at December 31, 2022, respectively.

#### Asset Retirement Obligation

We record a liability for asset retirement obligation at fair value in the period in which it is incurred and a corresponding increase in the carrying amount of the related long-lived assets.

#### Fair Value Considerations

We follow ASC 820, "Fair Value Measurements and Disclosures," as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company's financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

There are three levels of inputs to fair value measurements – Level 1, meaning the use of quoted prices for identical instruments in active markets; Level 2, meaning the use of quoted prices for similar instruments in active

markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; and Level 3, meaning the use of unobservable inputs. We use Level 1 inputs for fair value measurements whenever there is an active market, with actual quotes, market prices, and observable inputs on the measurement date. We use Level 2 inputs for fair value measurements whenever there are quoted prices for similar securities in an active market or quoted prices for identical securities in an inactive market. We use observable market data whenever available.

### **RESULTS OF OPERATIONS**

	For the three me Septembe		For the nine months ended September 30,	
	2023	2022	2023	2022
	(US \$ in thousands)		(US \$ in thousands)	
Operating costs and expenses:				
General and administrative expenses	1,332	1,636	4,106	4,621
Other	379	719	1,978	2,376
Post impairment of unproved oil and gas properties	36	-	129	-
Subtotal Operating costs and expenses	1,747	2,355	6,213	6,997
Other expense (income), net	(4)	19	3	140
Net loss	1,743	2,374	6,216	7,137

Revenue. We currently have no revenue generating operations.

*Operating costs and expenses.* Operating costs and expenses for the three and nine months ended September 30, 2023 were \$1,747,000 and \$6,213,000, respectively, compared to \$2,355,000 and \$6,997,000, respectively, for the three and nine months ended September 30, 2022.

*General and administrative expenses.* General and administrative expenses ("G&A expenses") for the three and nine months ended September 30, 2023 were \$1,332,000 and \$4,106,000, respectively, compared to \$1,636,000 and \$4,621,000, respectively, for the three and nine months ended September 30, 2022. This expense grouping includes salaries, benefits, stock option expenses and professional fees. G&A expenses decreased \$304,000, or 19%, during the most recent quarter versus the prior year primarily due to lower expenses associated with stock option grants. G&A expenses decreased \$515,000, or 11%, primarily due to lower expenses associated with stock option grants.

*Other expense.* Other expenses during the three and nine months ended September 30, 2023 were \$379,000 and \$1,978,000, respectively, compared to \$719,000 and \$2,376,000, respectively, for the three and nine months ended September 30, 2022. Other general and administrative expenses are comprised of non-compensation and non-professional expenses incurred. Other expenses decreased \$340,000, or about 47%, for the three months ended September 30, 2023 as a result of lower annual meeting expenses in 2023 and lower travel expenses. Other expenses for the nine months ended September 30, 2023 decreased \$398,000, or 17%, primarily due to lower annual meeting expenses.

*Post Impairment of unproved oil and gas properties.* Post Impairment of unproved oil and gas properties expenses during the three and nine months ended September 30, 2023 were \$36,000 and \$129,000 compared to nil and nil for the three and nine months ended September 30, 2022. The expenses recorded in 2023 are post impairment charges to the impairment recorded during 2022 related to the MJ-2 well.

*Other expense (income), net.* Other expenses (income) during the three and nine months ended September 30, 2023 were (\$4,000) and \$3,000, respectively, compared to \$19,000 and \$140,000, respectively, for the three and nine months ended September 30, 2022. The expenses in this category are comprised of foreign currency exchange costs, primarily the New Israeli Shekel (NIS) to the US dollar, and financial expenses/income. Overall, for the nine months ended September 30, 2022, total expenses in this category are \$121,000 lower due to the relative strengthening of the USD to the NIS during 2023.

*Net Loss.* Net loss for the three and nine months ended September 30, 2023 was \$1,743,000 and \$6,216,000 compared to \$2,374,000 and \$7,137,000 for the three and nine months ended September 30, 2022.

#### Liquidity and Capital Resources

Liquidity is a measure of a company's ability to meet potential cash requirements. As discussed above, we have historically met our capital requirements through the issuance of common stock as well as proceeds from the exercise of warrants and options to purchase common shares.

Our ability to continue as a going concern is dependent upon obtaining the necessary financing to complete further exploration and development activities and generate profitable operations from our oil and natural gas interests in the future. As we have expressed earlier in this Form 10-Q, our operations are temporarily suspended due to the Israel-Hamas war. Although the war's impact on our cash generation is not specifically known, the Company has been able to generate needed capital under our DSPP since 2013 and through various equity private placements prior to 2013. The Company plans to continue issuing its common shares through the DSPP (see Footnote 3 for a new Unit program announced on November 6, 2023). Our current operations are dependent upon the adequacy of our current assets to meet our current expenditure requirements and the accuracy of management's estimates of those requirements. Should those estimates be materially incorrect, our ability to continue as a going concern will be impaired. Our financial statements for the nine months ended September 30, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We have incurred a history of operating losses and negative cash flows from operations. Therefore, there is substantial doubt about our ability to continue as a going concern for one year from the date the financials were issued.

At September 30, 2023, we had approximately \$510,000 in cash and cash equivalents compared to \$1,735,000 at December 31, 2022, which does not include any restricted funds. Our working capital (current assets minus current liabilities) was (\$108,000) at September 30, 2023 and \$661,000 at December 31, 2022.

As of September 30, 2023, we provided bank guarantees to various governmental bodies (approximately \$930,000) and others (approximately \$85,000) in respect of our drilling operation in the aggregate amount of approximately \$1,015,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts in Israel and are reported on the Company's balance sheets as fixed short-term bank deposits restricted.

During the nine months ended September 30, 2023, cash used in operating activities totaled \$3,909,000. Cash provided by financing activities during the nine months ended September 30, 2023 was \$4,370,000 and is primarily attributable to proceeds received from the Dividend Reinvestment and Stock Purchase Plan (the "DSPP" or the "Plan"). Net cash used in investing activities such as unproved oil and gas properties, equipment and spare parts was \$2,045,000 for the nine months ended September 30, 2023.

During the nine months ended September 30, 2022, cash used in operating activities totaled \$4,719,000. Cash provided by financing activities during the nine months ended September 30, 2022 was \$16,473,000 and is primarily attributable to proceeds received from the Dividend Reinvestment and Stock Purchase Plan (the "DSPP" or the "Plan"). Net cash used in investing activities such as unproved oil and gas properties, equipment and spare parts was \$13,333,000 for the nine months ended September 30, 2022.

Accounting standards require management to evaluate our ability to continue as a going concern for a period of one year subsequent to the date of the filing of this Form 10-Q. We expect to incur additional significant expenditures to further our exploration and development programs. While we raised approximately \$391,000 during the period October 1, 2023 through November 7, 2023, we will need to raise additional funds in order to continue our exploration and development activities in our license area. Additionally, we estimate that, when we are not actively drilling a well, our expenditures are approximately \$600,000 per month excluding exploratory operational activities. However, when we are actively drilling a well, we estimate an additional minimum expenditure of approximately \$2,500,000 per month. The above estimates are subject to change. Subject to the qualifications specified below, management believes that our existing cash balance, excluding anticipated proceeds under the DSPP, will be sufficient to finance our plan of operations through November 2023.

The outbreak of the coronavirus and the Israel-Hamas war have to date significantly disrupted business operations. The extent to which the coronavirus and the war impacts our operations, specifically our capital raising efforts, as well as our ability to continue our exploratory efforts, will depend on future developments, which are highly uncertain and cannot be predicted with confidence.

No assurance can be provided that we will be able to raise the needed operating capital.

Even if we raise the needed funds, there are factors that can nevertheless adversely impact our ability to fund our operating needs, including (without limitation), unexpected or unforeseen cost overruns in planned non-drilling exploratory work in existing license areas, the costs associated with extended delays in undertaking the required exploratory work, and plugging and abandonment activities which is typical of what we have experienced in the past.

The financial information contained in these consolidated financial statements has been prepared on a basis that assumes that we will continue as a going concern for one year from the date the financials were issued, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. This financial information and these condensed consolidated financial statements do not include any adjustments that may result from the outcome of this uncertainty.

**Off-Balance Sheet Arrangements** 

We do not currently use any off-balance sheet arrangements to enhance our liquidity or capital resource position, or for any other purpose.

### **Recently Issued Accounting Pronouncements**

The Company does not believe that the adoption of any recently issued accounting pronouncements in 2023 had a significant impact on our financial position, results of operations, or cash flow.

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates.

*Foreign Currency Exchange Rate Risks.* A portion of our expenses, primarily labor expenses and certain supplier contracts, are denominated in New Israeli Shekels ("NIS"). As a result, we have significant exposure to the risk of fluctuating exchange rates with the U.S. Dollar ("USD"), our primary reporting currency. During the period January 1, 2023 through September 30, 2023, the USD has fluctuated by approximately 8.7% against the NIS (the USD strengthened relative to the NIS). Also, during the period January 1, 2022 through December 31, 2022, the USD fluctuated by approximately 13.2% against the NIS (the USD strengthened relative to the NIS). Continued strengthening of the US dollar against the NIS will result in lower operating costs from NIS denominated expenses. To date, we have not hedged any of our currency exchange rate risks, but we may do so in the future.

Interest Rate Risk. Our exposure to market risk relates to our cash and investments. We maintain an investment portfolio of short-term bank deposits and money market funds. The securities in our investment portfolio are not leveraged, and are, due to their very short-term nature, subject to minimal interest rate risk. We currently do not hedge interest rate exposure. Because of the short-term maturities of our investments, we do not believe that a change in market interest rates would have a significant negative impact on the value of our investment portfolio except for reduced income in a low interest rate environment. At September 30, 2023 we had cash, cash equivalents and short-term and long-term bank deposits, including restricted Israeli deposits, of approximately \$1,530,000. The weighted average annual interest rate related to our cash and cash equivalents for the three and nine months ended September 30, 2023, exclusive of funds at US banks that earn no interest, was approximately 4.45% and 3.51%, respectively.

The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

### **ITEM 4. CONTROLS AND PROCEDURES**

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms. As of September 30, 2023, our chief executive officer and our chief financial officer conducted an evaluation of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2023.

#### **Changes in Internal Control over Financial Reporting**

There were no changes in internal controls over financial reporting that occurred during the quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

### PART II—OTHER INFORMATION

### **ITEM 1. LEGAL PROCEEDINGS**

#### Securities and Exchange Commission ("SEC") Investigation

As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation, which we did.

On April 5, 2023, the Company received from the Fort Worth Regional Office of the SEC written notice to the Company concluding the investigation as to the Company and that the SEC does "not intend to recommend an enforcement action by the Commission against Zion."

#### Litigation

From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes.

The Company is not subject to any litigation at the present time.

### **ITEM 1A. RISK FACTORS**

During the quarter ended September 30, 2023, there were no material changes to the risk factors previously reported in our Annual Report on Form 10-K for the year ended December 31, 2022. However, as described in Footnote 7 – Subsequent Events, the Gaza militant terrorist organization Hamas infiltrated southern Israel on October 7, 2023, and Israel subsequently declared war on Hamas. We are, therefore, adding an additional risk factor as follows:

Our exploration focus on the nation of Israel subjects us to operational risks associated with various uncertainties associated with wars and skirmishes between Israel and other organizations and/or countries, including, but not limited to, Hamas, Hezbollah, Palestinian Islamic Jihad and Iran.

Our operation requires us to bring certain equipment, supplies and personnel into Israel and we also require the cooperation and approval of several departments, agencies and ministries within Israel. When Israel is at war and all of Israel's national focus is on accomplishing its wartime objectives, our ability to pursue our exploration program is adversely affected. We, therefore, have no way to determine how long Israel will remain at war and the resulting impacts on our business.

### ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

None.

### **ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

# **ITEM 4. MINE SAFETY DISCLOSURES**

None.

### **ITEM 5. OTHER INFORMATION:**

None.

# **ITEM 6. EXHIBITS**

# Exhibit Index:

10.1	New Megiddo Valleys License 434
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 under the Exchange Act
31.2	Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 under the Exchange Act
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished only)
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished only)
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ZION OIL & GAS, INC. (Registrant)

By: /s/ Robert W.A. Dunn Robert W. A. Dunn Chief Executive Officer (Principal Executive Officer)

Date: November 9, 2023

By: /s/ Michael B. Croswell Jr. Michael B. Croswell Jr. Chief Financial Officer (Principal Financial and Accounting Officer)

Date: November 9, 2023